RG
AMBI

Redmile Group’s Ambit Biosciences Corp AMBI Stock Holding History

Redmile Group’s Portfolio AMBI Stock Details AMBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-367,602
Closed -$3.35M – 69
2014
Q1 		$3.35M Sell
367,602
-178,383
-33% -$1.89M 0.4% 44
2013
Q4 		$5.26M Buy
+545,985
New +$7.29M 0.65% 45

Other funds holding AMBI

FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group's AMBI Position: Q2 2014 in Review

Redmile Group sold out of Ambit Biosciences Corp (AMBI) in Q2 2014, closing a stake of 367,602 shares — an estimated $3.35M sold.

Redmile Group first reported a position in AMBI in Q4 2013 and held it in 2 quarters. The position peaked at $5.26M in Q4 2013. 36 funds tracked by Wall St. Rank hold AMBI as of Q2 2014.

  • Redmile Group reported no remaining Ambit Biosciences Corp position as of Q2 2014 after selling out during the quarter.
  • Redmile Group sold 367,602 Ambit Biosciences Corp shares in Q2 2014, an estimated $3.35M.
  • Redmile Group first reported a position in Ambit Biosciences Corp in Q4 2013 and held it in 2 quarters.
  • Redmile Group's Ambit Biosciences Corp position peaked at $5.26M in Q4 2013.
  • 36 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q2 2014.

Based on Redmile Group's 13F filing for Q2 2014, filed 15 Aug 2014.